Brain renin-angiotensin-A new look at an old system

Progress in Neurobiology

Volumn 95, Issue 1, 2011, Pages 49-67

  Wright, John W ^a   Harding, Joseph W ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Alcohol consumption; Alzheimer's disease; Angiotensin II; Angiotensin IV; Angiotensin receptors; C Met receptor; Cerebroprotection; Diabetes; Insulin regulated aminopeptidase; Parkinson's disease

Indexed keywords

AMINOPEPTIDASE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN 4 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; LOSARTAN; OLMESARTAN; PEPTIDASE; RECEPTOR SUBTYPE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TELMISARTAN; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VALSARTAN;

ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN PROTECTION; BRAIN REGION; CARDIOVASCULAR FUNCTION; DEPRESSION; DIABETES MELLITUS; DRUG EFFICACY; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; LIGAND BINDING; MEMORY DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEIZURE; STRESS; STRESS ULCER;

ANGIOTENSINS; ANIMALS; BRAIN; HEPATOCYTE GROWTH FACTOR; HUMANS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, ANGIOTENSIN; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 79960675107     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2011.07.001     Document Type: Review

References (349)

1. Aizawa K., Sato S., Terakawa M., Saitoh D., Tsuda H., Ashida H., Obara M. Accelerated adhesion of grafted skin by laser-induced stress wave-based gene transfer of hepatocyte growth factor. J. Biomed. Opt. 2009, 14:064043.
2. Akimoto M., Baba A., Ikeda-Matsuo Y., Yamada M.K., Itamura R., Nishiyama N., Ikegaya Y., Matsuki N. Hepatocyte growth factor as an enhancer of NMDA currents and synaptic plasticity in the hippocampus. Neuroscience 2004, 128:155-162.
3. Albiston A.L., Allen A.M., Mendelsohn F.A., Ping S.E., Barrett G.L., Murphy M., Morris M.J., McDowall S.G., Chai S.Y. Effect of I.C.V. injection of AT4 receptor ligands, NLE1-angiotensin IV and LVV-hemorphin 7, on spatial learning in rats. Neuroscience 2004, 124:341-349.
4. Albiston, A.L., Diwakaria, S., Fernando, R.N., Mountford, S.J., Yeatman, H., Morgan, B., Pham, V., Holien, J.K., Parker, M.W., Thompson, P.E., Chai, S.Y., 2011. Br. J. Pharmacol. (Epub ahead of print).
5. Albiston A.L., Fernando R.N., Yeatman H.R., Burns P., Ng L., Daswani D., Diwakarla S., Pham V., Chai S.Y. Gene knockout of insulin-regulated aminopeptidase: loss of the specific binding site for angiotensin IV and age-related deficit in spatial memory. Neurobiol. Learn. Mem. 2010, 93:19-30.
6. Albiston A.L., McDowall S.G., Matsacos D., Sim P., Clune E., Mustafa T., Lee J., Mendelsohn F.A., Simpson R.J., Connolly L.M., Chai S.Y. Evidence that the angiotensin IV (AT4) receptor is the enzyme insulin regulated aminopeptidase. J. Biol. Chem. 2001, 276:48263-48266.
7. Albiston A.L., Morton C.J., Ng H.I., Pham V., Yeatman H.R., Ye S., Fernando R.N., De Bundel D., Ascher D.B., Mendelsohn F.A., Parker M.W., Chai S.Y. Identification and characterization of a new cognitive enhancer based on inhibition of insulin-regulated aminopeptidase. FASEB J. 2008, 22:4209-4217.
8. Albiston A.L., Mustafa T., McDowall S.G., Mendelsohn F.A., Lee J., Chai S.Y. AT(4) receptor is insulin-regulated membrane aminopeptidase: potential mechanisms of memory enhancement. Trends Endocrinol. Metab. 2003, 14:72-77.
9. Albiston A.L., Peck G.R., Yeatman H.R., Fernando R., Ye S., Chai S.Y. Therapeutic targeting of insulin-regulated aminopeptidase: heads and tails?. Pharmacol. Ther. 2007, 116:417-427.
10. Albiston A.L., Pederson E.S., Burns P., Purcell B., Wright J.W., Harding J.W., Mendelsohn F.A., Weisinger R.S., Chai S.Y. Attenuation of scopolamine-induced learning deficits by LVV-hermorphin-7 in rats in the passive avoidance and water maze paradigms. Behav. Brain Res. 2004, 154:239-243.
11. Albrecht D., Broser M., Kruger H. Excitatory action of angiotensins II and IV on hippocampal neuronal activity in urethane anesthetized rats. Regul. Pept. 1997, 70:105-109.
12. Allen A.M., MacGregor D.P., Chai S.Y., Donnan G.A., Daczmarczyk S., Richardson K., Kainins R., Ireton J., Mendelsohn F.A. Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia. Ann. Neurol. 1992, 32:339-344.
13. Allen A.M., Oldfield B.J., Giles M.E., Paxinos G., McKinley M.J., Mendelsohn F.A. Localization of angiotensin receptors in the nervous system. Handbook of Chemical Neuroanatomy 2000, 79-124. Elsevier, Amsterdam. R. Quirion, A. Bjorklund, T. Hodfelt (Eds.).
14. Andersson H., Demaegdt H., Vauquelin G., Lindeberg G., Karlen A., Hallberg M. Ligands to the (IRAP)/AT4 receptor encompassing a 4-hydroxydiphenylmethane scaffold replacing Tyr2. Biorg. Med. Chem. 2008, 16:6924-6935.
15. Armando I., Seltzer A., Bregonzio C., Saavedra J.M. Stress and angiotensin II: novel therapeutic opportunities. Curr. Drug Targets-CNS & Neurol. Dis. 2003, 2:413-419.
16. Arkwright P.D., Beilin L.J., Rouse I., Armstrong B.K., Vandongen R. Alcohol: effect on blood pressure and predisposition to hypertension. Clin. Sci. (Lond.) 1981, 61(Suppl. 7):373s-375s.
17. Axen A., Andersson H., Lindeberg G., Ronnholm H., Kortesmaa J., Demaegdt H., Vauquelin B., Karlen A., Hallberg M. Small potent ligands to the insulin-regulated aminopeptidase (IRAP)/AT(4) receptor. J. Pept. Sci. 2007, 13:434-444.
18. Babior B.M. NADPH oxidase. Curr. Opin. Immunol. 2004, 16:42-47.
19. Bae M.H., Bissonette G.B., Mars W.M., Michalopoulos G.K., Achim C.L., Depireux D.A., Powell E.M. Hepatocyte growth factor (HGF) modulates GABAergic inhibition and seizure susceptibility. Exp. Neurol. 2010, 221:129-135.
20. Banegas I., Prieto I., Vives F., Alba F., de Gasparo M., Segarra A.B., Hermoso F., Duran R., Ramírez M. Brain aminopeptidases and hypertension. J. Renin Angiotensin Aldosterone Syst. 2006, 7:129-134.
21. Basso N., Paglia N., Stella I. Protective effect of the inhibition of the renin-angiotensin system on aging. Regul. Pept. 2005, 128:247-252.
22. Beatty W.W., Hames K.A., Blanco C.R., Nixon S.J., Tivis L.J. Visuospatial perception, construction and memory in alcoholism. J. Stud. Alcohol 1996, 57:136-143.
23. Becker C., Jick S.S., Meier C.R. Use of antihypertensives and the risk of Parkinson disease. Neurology 2008, 70:1438-1444.
24. Bennett J.P., Snyder S.H. Angiotensin II binding to mammalian brain membranes. J. Biol. Chem. 1976, 251:7423-7430.
25. Benoist, C.C., Wright, J.W., Wayman, G.A., Harding, J.W. Facilitation of hippocampal synaptogenesis and spatial memory by C-terminal truncated Nle1-angiotensin IV analogues. J. Pharmacol. Exp. Ther., in press.
26. 4 receptor from bovine aortic endothel photosensitive analogues of angiotensin IV. Biochemistry 1998, 37:4280-4287.
27. Bichu P., Nistala R., Khan A., Sowers J.R., Whaley-Connell A. Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vasc. Health Risk Manag. 2009, 5:129-140.
28. Bondy B. Common genetic factors for depression and cardiovascular disease. Dialogues Clin. Neurosci. 2007, 9:19-28.
29. 2 receptors do not interact with guanine nucleotide binding proteins. Eur. J. Pharmacol. 1991, 207:157-163.
30. Bowden S.C., McCarter R.J. Spatial memory in alcohol-dependent subjects: using a push-button maze to test the principle of equiavailability. Brain Cognition 1993, 22:51-62.
31. 2 dopamine receptor blockade prevents cognitive effects of AngIV and des-Phe6 AngIV. Physiol. Behav. 2006, 88:152-159.
32. Braszko J.J. Dopamine D4 receptor antagonist L745,870 abolishes cognitive effects of intracerebroventricular angiotensin IV and des-Phe(6)-AngIV in rats. Eur. Neuropsychopharmacol. 2009, 19:85-91.
33. 6 angiotensin IV. Neurosci. Biobehav. Rev. 2010, 34:343-350.
34. Braszko J.J., Kulakowska A., Karwowska-Polecka W. CGP 42112A antagonism of the angiotensin II and angiotensin II(3-7) facilitation of recall in rats. Pharmacol. Res. 1998, 38:461-468.
35. Braszko J.J., Kupryszewski G., Witczuk B., Wisniewski K. Angiotensin II (3-8)-hexapeptide affects motor activity, performance of passive avoidance, and a conditioned avoidance response in rats. Neuroscience 1988, 27:777-783.
36. Braszko J.J., Walesiuk A., Wielgat P. Cognitive effects attributed to angiotensin II may result from its conversion to angiotensin IV. J. Renin Angiotensin Aldosterone Syst. 2006, 7:168-174.
37. Braszko J.J., Wielgat P., Walesiuk A. Effect of D(3) dopamine receptor blockade on the cognitive effects of angiotensin IV in rats. Neuropeptides 2008, 42:301-309.
38. Braszko J.J., Wlasienko J., Koziolkiewicz W., Janecka A., Wisniewski K. The 3-7 fragment of angiotensin II is probably responsible for its psychoactive properties. Brain Res. 1991, 542:49-54.
39. Bregonzio C., Armando I., Ando H., Jezova M., Baiardi G., Saavedra J.M. Anti-inflammatory effects of angiotensin II AT1 receptor antagonism prevent stress-induced gastric injury. Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 285:G414-G423.
40. Bregonzio C., Seltzer A., Armando I., Pavel J., Saavedra J. Angiotensin II AT(1) receptor blockade selectively enhances brain AT(2) receptor expression, and abolishes the cold-restraint stress-induced increase in tyrosine hydroxylase mRNA in the locus coeruleus of spontaneously hypertensive rats. Stress 2008, 11:457-466.
41. Buggy J., Johnson A.K. Angiotensin-induced thirst: effects of third ventricle obstruction and periventricular ablation. Brain Res. 1978, 149:117-128.
42. Cairns V., Keil U., Kleinbaum D., Doering A., Stieber J. Alcohol consumption as a risk factor for high blood pressure. Munich Blood Pressure Study. Hypertension 1984, 6:124-131.
43. Carey R.M., Siragy H.M. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol. Metab. 2003, 14:274-281.
44. Castren E., Saavedra J.M. Repeated stress increases the density of angiotensin II binding sites in rat paraventricular nucleus and subfornical organ. Endocrinology 1988, 122:370-372.
45. Chabrashvili T., Kitiyakara C., Blau J. Effects of ANGII type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am. J. Physiol. 2003, 285:R117-R124.
46. 4 receptor) in the human forebrain, midbrain and pons as visualized by in vitro receptor autoradiography. J. Chem. Neuroanat. 2000, 20:339-348.
47. 4 receptor. CMLS Cell Mol. Life Sci. 2004, 61:2728-2737.
48. Chai S.Y., McKenzie J.S., McKinley M.J., Mendelsohn F.A. Angiotensin converting enzyme in the human basal forebrain and midbrain visualized by in vitro autoradiography. J. Comp. Neurol. 1990, 291:179-194.
49. Chai S.Y., Mendelsohn F.A., Paxinos G. Angiotensin converting enzyme in rat brain visualized by quantitative in vitro autoradiography. Neuroscience 1987, 20:615-627.
50. Chai S.Y., Yeatman H.R., Parker M.W., Ascher D.B., Thomspon P.E., Mulvery H.T., Albiston A.L. Development of cognitive enhancers based on inhibition of insulin-regulated aminopeptidase. BMC Neurosci. 2008, 9(Suppl. 2):S14.
51. Chaturvedi N., Porta M., Klien R., Orchard T., Fuller J., Parving H.H., Bilous R., Sjolie A.K. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomized, placebo-controlled trials. Lancet 2008, 372:1394-1402.
52. Chauvel E.N., Llorens-Cortes C., Coric P., Wilk S., Roques B.P., Fournie-Zaluski M.C. Differential inhibition of aminopeptidase A and aminopeptidase N by new-amino thiols. J. Med. Chem. 1994, 37:2950-2957.
53. Chen J.K., Zimpelmann J., Harris R.C., Burns K.D. Angiotensin IV induces tyrosine phosphorylation of focal adhesion kinase and paxillin in proximal tubule cells. Am. J. Physiol. Renal Physiol. 2001, 280:F980-F988.
54. Chen P., Guo A.M., Edwards P.A., Trick G., Scicli A.G. Role of NADPH oxidase and ANG II in diabetes-induced retinal leukostasis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 293:1619-1629.
55. Chen S.G.Y., Si J., Rifai A., Dworkin L.D., Gong R. Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. Kidney Int. 2008, 74:1128-1138.
56. Chiarelli F., Di Marzio D., Santilli F., Mohn A., Blasetti A., Cipollone F., Mezzetti A., Verrotti A. Effects of irbesartan on intracellular antioxidant enzyme expression and activity in adolescents and young adults with early diabetic angiopathy. Diabet. Care 2005, 28:1690-1697.
57. Cippitelli A., Damadzic R., Frankola K., Goldstein A., Thorsell A., Singley E., Eskay R.L., Heilig M. Alcohol-induced neurodegeneration, suppression of transforming growth factor-β, and cognitive impairment in rats; prevention by group II metabotropic glutamate receptor activation. Biol. Psychiatry 2010, 67:823-830.
58. Collins M.A., Corso T.D., Neafsey E.J. Neuronal degeneration in rat cerebrocortical and olfactory regions during subchronic binge intoxication with ethanol: possible explanation for olfactory deficits in alcoholics. Alcohol: Clin. Exp. Res. 1996, 20:284-292.
59. Comoglio P.M., Giordano S., Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 2008, 7:504-516.
60. Conway K., Price P., Harding K.G., Jiang W.G. The molecular and clinical impact of hepatocyte growth factor, its receptor, activators, and inhibitors in wound healing. Wound Repair Regen. 2006, 14:2-10.
61. Conway K., Ruge F., Price P., Harding K.G., Jiang W.G. Hepatocyte growth factor regulation: an integral part of why wounds become chronic. Wound Repair Regen. 2007, 15:683-692.
62. Cooke K.M., Frost G.W., Stokes G.S. Blood pressure and its relationship to low levels of alcohol consumption. Clin. Exp. Pharmacol. Physiol. 1983, 10:229-233.
63. Crews F.T., Braun C.J., Switzer R.C., Knapp D.J. Binge ethanol causes differential brain damage in young adolescent rats compared to adult rats. Alcohol: Clin. Exp. Res. 2000, 24:1712-1723.
64. Csernansky J.G., Dong H., Fagan A.M., Wang L., Xiong C., Holtzman D.M., Morris J.C. Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am. J. Psychiatry 2006, 163:2164-2169.
65. Dalmay F., Pesteil F., Allard J., Nisse-Durgeat S., Fernandez L., Fournier A. Angiotensin IV decreases acute stroke mortality in the gerbil. Hypertension 2001, 14:56A.
66. Danielyan L., Klein R., Hanson L.R., Buadze M., Schwab M., Gleiter C.H., Frey W.H. Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res. 2010, 13:195-201.
67. Danser A.H., Derx F.H., Admiraal P.J., Deinum J., de Jong P.T., Schalekamp M.A. Angiotenisn levels in the eye. Invest. Ophthalmol. Vis. Sci. 1994, 35:1008-1018.
68. Danser A.H., Van den Dorpel M.A., Dienum J., Derkx F.H., Franken A.A., Peperkamp E., de Jong P.T., Schalekamp M.A. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J. Clin. Endocrinol. Metab. 1989, 68:160-167.
69. Date I., Takagi N., Takagi K., Kago T., Matsumoto K., Nakamura T., Takeo S. Hepatocyte growth factor attenuates cerebral ischemia-induced learning dysfunction. Biochem. Biophys. Res. Commun. 2004, 319:1152-1158.
70. Date I., Takagi N., Takagi K., Kago T., Matsumoto K., Nakamura T., Takeo S. Hepatocyte growth factor imporved learning and memory dysfunction of microsphere-embolized rats. J. Neurosci. Res. 2004, 78:442-453.
71. Davis C.J., Kramar E.A., De A., Meighan P.C., Simasko S.M., Wright J.W., Harding J.W. AT4 receptor activation increases intracellular calcium influx and induces a non-N-methyl-D-aspartate dependent form of long-term potentiation. Neuroscience 2006, 137:1369-1379.
72. 1 receptor subtype in the effects of angiotensin IV and LVV-haemorphin 7 on hippocampal neurotransmitter levels and spatial working memory. J. Neurochem. 2010, 112:1223-1234.
73. De Bundel D., Smolders I., Vanderheyden P., Michotte Y. AngII and AngIV: unraveling the mechanism of action on synaptic plasticity, memory, and epilepsy. CNS Neurosci. Ther. 2008, 14:315-339.
74. De Bundel D., Smolders I., Yang R., Albiston A.L., Michotte Y., Chai S.Y. Angiotensin IV and LVV-haemorphin 7 enhance spatial working memory in rats: effects on hippocampal glucose levels and blood flow. Neurobiol. Learn. Mem. 2009, 92:19-26.
75. de Gasparo M., Catt K.J., Inagami T., Wright J.W., Unger T. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 2000, 52:415-472.
76. de Gasparo M., Husain A., Alexander W., Catt K.J., Chiu A.T., Drew M., Goodfriend T., Harding J.W., Inagami T., Timmermans P.B. Proposed update of angiotensin receptor nomenclature. Hypertension 1995, 25:924-939.
77. Deicken R.F. Captopril treatment of depression. Biol. Psychiatry 1986, 12:1425-1428.
78. Demaegdt H., Lenaerts P.J., Swales J., De Backer J.P., Laeremans H., Le M.T., Kersemans K., Vogel l.K., Michotte Y., Vanderheyden P., Vauquelin G. Angiotensin AT4 receptor ligand interaction with cystinyl aminopeptidase and aminopeptidase N: [125I] angiotensin IV only binds to the cystinyl aminopeptidase apo-enzyme. Eur. J. Pharmacol. 2006, 28:19-27.
79. Dengerink H.A., Mead J.D., Bertilson H.S. Individual differences in response to alcohol. Vasoconstriction and vasodilation. J. Stud. Alchol. 1978, 39:12-18.
80. Dinh D.T., Grauman A.G., Johston C.I., Fabiani M.E. Angiotensin receptors: distribution, signaling and function. Clin. Sci. 2001, 100:481-492.
81. Dulin N., Madhun Z.T., Chang C.H., Berti-Mattera L., Dickens D., Douglas J.G. Angiotensin IV receptors and signaling in opossum kidney cells. Am. J. Physiol 1995, 269:F644-F652.
82. Dupont A.G., Brouwers S. Brain angiotensin peptides regulate sympathetic tone and blood pressure. J. Hypertens. 2010, 28:1599-1610.
83. Duron E., Hanon O. Antihypertensive treatments, cognitive decline, and dementia. J. Alzheimers Dis. 2010, 20:903-914.
84. Ebrahimian T.G., Tamarat R., Clergue M., Duriez M., Levy B.I., Silvestre J.S. Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Arterioscler. Thromb. Vasc. Biol. 2005, 25:65-70.
85. Ehlers M.R., Riordan J.F. Angiotensin-converting enzyme: new concepts concerning its biological role. Biochemistry 1989, 28:5311-5318.
86. Ellul J., Archer N., Foy C.M., Poppe M., Boothby H., Nicholas H., Brown R.G., Lovestone S. The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration. J. Neurol. Neurosurg. Psychiatry 2006, 78:233-239.
87. El Messari S., Ait-Ikhlef A., Ambroise D.H., Penicaud L., Arluison M. Expression of insulin-responsive glucose transporter GLUT4 mRNA in the rat brain and spinal cord: an in situ hybridization study. J. Chem. Neuroanat. 2002, 24:225-242.
88. El Messari S., Leloup C., Quignon M., Brisorgueil M.J., Penicaud L., Arluison M. Immunocytochemical localization of the insulin-responsive glucose transporter 4 (Glut4) in the rat central nervous system. J. Comp. Neurol. 1998, 399:492-512.
89. Esteban V., Ruperez M., Sanchez-Lopez E., Rodriguez-Vita j., Lorenzo O., Demaegdt H., Vanderheyden P., Egido J., Ruiz-ortega M. Angiotensin IV activates the nuclear transcription factor-kappaB and related proinflammatory genes in vascular smooth muscle cells. Circ. Res. 2005, 96:965-973.
90. Faber F., Gembardt F., Sun X., Muzutani S., Siems W.E., Walther T. Lack of angiotensin II conversion to angiotensin III increases water but not alcohol consumption in aminopeptidase A-deficient mice. Regul. Pept. 2006, 136:130-137.
91. Faure S., Chapot R., Tallet D., Javellaud J., Achard J.M., Oudart N. Cerebroprotective effect of angiotensin IV in experimental ischemic stroke in the rat mediated by AT(4) receptors. J. Physiol. Pharmacol. 2006, 57:329-342.
92. Fernando R.N., Albiston A.L., Chai S.Y. The insulin-regulated aminopeptidase IRAP is colocalised with GLUT4 in the mouse hippocampus-potential role in modulation of glucose uptake in neurons?. Eur. J. Neurosci. 2008, 28:588-598.
93. Fernando R.N., Larm J., Albiston A.L., Chai S.Y. Distribution and cellular localization of insulin-regulated aminopeptidase in the rat central nervous system. J. Comp. Neurol. 2005, 487:372-390.
94. Fernando R.N., Luff S.E., Albiston A.L., Chai S.Y. Sub-cellular localization of insulin-regulated membraine aminopeptidase, IRAP to vesicles in neurons. J. Neurochem. 2007, 102. pp. 996-976.
95. Ferrario C.M., Chappell M.D. Novel angiotensin peptides. Cell. Mol. Life Sci. 2004, 61:2720-2727.
96. Fitts D.A. Angiotensin and captopril increase alcohol intake. Pharmacol. Biochem. Behav. 1993, 45:35-43.
97. Fitts D.A., Masson D.B. Forebrain sites of action for drinking and salt appetite to angiotensin or captopril. Behav. Neurosci. 1989, 103:865-872.
98. Fitzsimons J.T. Angiotensin stimulation of the central nervous system. Rev. Physiol. Biochem. Pharmacol. 1980, 87:117-167.
99. Folli F., Saad M.J., Velloso L., Hansen H., Carandente O., Feener E.P., Kahn C.R. Crosstalk between insulin and angiotensin II signaling systems. Exp. Clin. Endocrinol. Diabetes 1999, 107:133-139.
100. Förstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat. Clin. Pract. Cardiovasc. Med. 2008, 5:338-349.
101. Fournier A., Messerti F.H., Achard J.M., Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J. Am. Coll. Cardiol. 2004, 43:1343-1347.
102. Fournier A., Oprisiu-Fournier R., Serot J.M., Godefroy O., Achard J.M., Faure S., Mazouz H., Temmar M., Albu A., Bordet R., Hanon O., Gueyffier F., Wang J., Black S., Sato N. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev. Neurother. 2009, 9:1413-1431.
103. Franken A.A., Derkx F.H., Schalekamp M.A., Man in t'Veld A.J., Hop W.C., van Rens E.H., de Jong P.T. Association of high plasma prorenin with diabetic retinopathy. J. Hypertens. 1988, (Suppl. 6):S461-S463.
104. Friedman G.D., Klatsky A.L., Siegelaub A.B. Alcohol, tobacco, and hypertension. Hypertension 1982, 4(5 Pt. 2):III143-III150.
105. Fukumoto M., Takai S., Ishizaki E., Suglyama T., Oku H., Jin D., Sakaguchi M., Sakonjo H., Ikeda T., Miyazaki M. Involvement of angiotensin II-dependent fascular endothelial growth factor gene expression via NADPH oxidase in the retina in a type 2 diabetic rat model. Curr. Eye Res. 2008, 33:885-891.
106. Funatsu H., Yamashita H., Ikeda T., Nakanishi Y., Kitano S., Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am. J. Ophthalmol. 2002, 133:537-543.
107. Galletti F., Cupini L.M., Corbelli I., Calabresi P., Sarchielli P. Pathophysiological basis of migraine prophylaxis. Prog. Neurobiol. 2009, 89:176-192.
108. Ganong W.F., Murakami K. The role of angiotensin II in the regulation of ACTH secretion. Ann. N.Y. Acad. Sci. 1987, 512:176-186.
109. Ganten D., Boucher R., Genest J. Renin activity in brain tissue of puppies and adult dogs. Brain Res. 1971, 33:557-559.
110. Ganten D., Marquez-Julio A., Granger P., Hayduk K., Karsunky K.P., Boucher R., Genest J. Renin in dog brain. Am. J. Physiol. 1971, 221:1733-1737.
111. Gard P.R. The role of angiotensin II in cognition and behaviour. Eur. J. Pharmacol. 2002, 438:1-14.
112. Gard P.R. Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. Expert Opin. Ther. Targets 2004, 8:7-14.
113. Gard P.R. Cognitive-enhancing effects of angiotensin IV. BMC Neurosci. 2008, 9(Suppl. 2):S2-S15.
114. Gard P.R., Mycroft N. Reduction of angiotensin II-induced drinking in rats by 21hour pretreatment with desipramine. J. Pharm. Pharmacol. 1991, 43(Suppl. 1).
115. Gard P.R., Mandy A., Sutcliffe M.A. Evidence of a possible role of altered angiotensin function in the treatment, but not aetiology, of depression. Biol. Psychiatry 1999, 45:1030-1034.
116. Gard P.R., Mandy A., Whiting J.M., Nickels D.P., Meakin A.J. Reduction of responses to angiotensin II by antidepressant drugs. Eur. J. Pharmacol. 1994, 264:295-300.
117. Garreau I., Chansel D., Vandermeersch S., Fruitier I., Piot J.M., Ardaillou R. Hemorphins inhibit angiotensin IV binding and interact with aminopeptidase N. Peptides 1998, 19:1339-1348.
118. Giacchetti G., Sechi L.A., Rilli S., Carey R.M. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol. Metab. 2005, 16:120-126.
119. Germain L., Chouinard G. Treatment of recurrent unipolar major depression with captopril. Biol. Psychiatry 1988, 23:637-641.
120. Germain L., Chouinard G. Captopril treatment of major depression with serial measurements of blood cortisol concentrations. Biol. Psychiatry 1989, 25:489-493.
121. Georgiev V., Kambourova T. Angiotensin II effects on the threshold of chemical convulsion seizures. Comp. Rendus de lAcad. Bulgare des Sci. 1983, 36:1599-1602. (Abstract).
122. Georgiev V., Lazarova M., Petkov V.D., Kambourova T. Interactions between angiotensin II, GABA and diazepam in convulsive seizures. Neuropeptides 1986, 7:329-336.
123. Gesualdo L., Ranicri E., Monno R., Rossiello M.R., Colucci M., Semeraro N., Grandaliano G., Schena F.P., Ursi M., Cerullo G. Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells. Kidney Int. 1999, 56:461-470.
124. Giardina W.J., Ebert D.M. Positive effects of captopril in the behavioural despair swim test. Biol. Psychiatry 1989, 25:697-702.
125. Glossmann H., Baukal A., Catt K.J. Angiotensin II receptors in bovine adrenal cortex. Modification of angiotensin II binding by guanyl nucleotides. J. Biol. Chem. 1974, 249:664-666.
126. 2-adrenoceptor antagonist treatment. Naunyn-Schmiedeberg's Arch. Pharmacol. 1985, 329:355-358.
127. Grammatopoulos T.N., Jones S.M., Ahmadi F.A., Hoover B.R., Snell L.D., Skoch J., Javeri V.V., Poczobutt A.M., Weyhenmeyer J.A., Zawada W.M. Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol. Neurodegener. 2007, 2:1.
128. Grammatopoulos T.N., Outeiro T.F., Hyman B.T., Standaert D.G. Angiotensin II protects against α-synuclein toxicity and reduces protein aggregation in vitro. Biochem. Biophys. Res. Commun. 2007, 363:846-851.
129. Grippo A.J., Johnson A.K. Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical disease models. Stress 2009, 12:1-21.
130. Grupp L.A. The renin-angiotensin system: a multidimensional source of control over alcohol consumption. Alcohol Alcohol. 1991, (Suppl. 1):421-426.
131. Grupp L.A., Perlanski E. Ethanol-induced changes in the spontaneous activity of single units in the hippocampus of the awake rat: a dose-response study. Neuropharmacology 1979, 18:63-70.
132. Grupp L.A., Perlanski E., Stewart R.B. Dietary salt and doca-salt treatments modify ethanol self-selection in rats. Behav. Neural. Biol. 1984, 40:239-250.
133. Grupp L.A., Perlanski E., Stewart R.B. Diet and diuretics in the reduction of voluntary alcohol drinking in rats. Alcohol Alcohol. 1986, 21:75-79.
134. 1B. Biochim. Biophys. Acta 1994, 1218:91-94.
135. Gupta M., Honos G.N., Velazquez E.J., Chung N., Oigman W., Maggioni A.P. Evidence for the efficacy of ARBs across the cardiovascular continuum. Curr. Med. Res. Opin. 2010, 26:1203-1218.
136. Gutierrez H., Dolcet X., Tolcos M., Davies A. HGF regulates the development of cortical pyramidal dendrites. Development 2004, 131:3717-3726.
137. Ha X.Q., Lv T.D., Hui L., Dong F. Effects of mesenchymal stem cells transfected with human hepatocyte growth factor gene on healing of burn wounds. Chin. J. Traumatol. 2010, 13:349-355.
138. Hajjar I.M., Keown M., Frost B. Antihypertensive agents for aging patients who are at risk for cognitive dysfunction. Curr. Hypert. Rep. 2005, 7:466-473.
139. 4/angiotensin IV system in mediating natriuresis in the rat. Peptides 2001, 22:935-944.
140. Handa R.K. Characterization and signaling of the AT(4) receptor in human proximal tubule epithelial (HK-2) cells. J. Am. Soc. Nephrol. 2001, 12:440-449.
141. Handa R.K., Harding J.W., Simasko S.M. Characterization and function of the bovine kidney epithelial angiotensin receptor subtype 4 using angiotensin IV and divalinal angiotensin IV as receptor ligands. J. Pharmacol. Exp. Ther. 1999, 291:1242-1249.
142. Hanesworth J.M., Sardinia J.F., Krebs L.T., Hall K.L., Harding J.W. Elucidation of a specific binding site for angiotensin II(3-8), angiotensin IV, in mammalian heart membranes. J. Pharmcol. Exp. Ther. 1993, 266:1036-1042.
143. Harding J.W., Cook V.I., Miller-Wing A.V., Hanesworth J.M., Sardinia M.F., Hall K.L., Stobb J.W., Swanson G.N., Coleman J.K., Wright J.W., Harding E.C. Identification of an AII (3-8) [AIV] binding site in guinea pig hippocampus. Brain Res. 1992, 583:340-343.
144. Hashimoto N., Yamanaka H., Fukuoka T., Obata K., Mashimo T., Naguchi K. Expression of hepatocyte growth factor in primary sensory neurons of adult rats. Brain Res. Mol. Brain Res. 2001, 97:83-88.
145. Healy D.P., Wilk S. Localization of immunoreactive glutamyl aminopeptidase in rat brain. II Distribution and correlation with angiotensin II. Brain Res. 1993, 606:295-303.
146. Heinemann A., Sattler V., Jocic M., Wienen W., Holzer P. Effect of angiotensin II and telmisartan, an angiotensin 1 receptor antagonist, on rat gastric mucosal blood flow. Aliment. Pharmacol. Ther. 1999, 13:347-355.
147. Herbst J.J., Ross S.A., Scott H.M., Bobin S.A., Morris N.J., Lienhard G.E., Keller S.R. Insulin stimulates cell surface aminopeptidase activity toward vasopressin in adipocytes. Am. J. Physiol. 1997, 272:E600-E606.
148. Hoogwerf B.J. Renin-angiotensin system blockade and cardiovascular and renal protection. Am. J. Cardiol. 2010, 105(Suppl.). pp. 30A-35A.
149. Inoue T. Dynamics of calcium and its roles in the dendrite of the cerebellar Purkinje cell. Keio J. Med. 2003, 52:244-249.
150. Isingrini E., Desmidt T., Belzung C., Camus V. Endothelial dysfunction: a potential target for geriatric depression and brain amyloid deposition in Alzheimer's disease?. Curr. Opin. Investig. Drugs 2009, 10:46-55.
151. Iwai N., Inagami T. Identification of two subtypes in the rat type 1 angiotensin II receptor. FEBS Lett. 1992, 298:257-260.
152. Izuhara Y., Sada T., Yanagisawa H., Koike H., Ohtomo S., Dan T., Ito S., Nangaku M., van Ypersele de Strihou C., Miyata T. A novel sartan derivative with very low angiotensin II Type 1 receptor affinity protects the kidney in Type 2 diabetic rats. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1767-1773.
153. 2 recognition sites in bovine adrenal cortex. Eur. J. Pharmacol. 1992, 219:319-322.
154. Jenkins T.A., Mendelsohn F.A., Chai S.Y. Angiotnsin-converitn enzyme modulates dopamine turnover in the striatum. J. Neurochem. 1997, 68:1304-1311.
155. Jenkins T.A., Wong J.Y., Howells D.W., Mendelsohn F.A., Chai S.Y. Effect of chronic angiotensin-converting enzyme inhibition on striatal dopamine content in the MPTP-treated mouse. J. Neurochem. 1999, 73:214-219.
156. Jensen G.B., Pakkenberg B. Do alcoholics drink their neurons away?. Lancet 1993, 342:1201-1204.
157. Jezova D., Ochedalski T., Kiss A., Aguilera G.J. Brain angiotensin II modulates sympathoadrenal and hypothalamic pituitary adrenocortical activation during stress. Neuroendocrinology 1998, 10:67-72.
158. Jiang W.G., Martin T.A., Parr C., Davies G., Matsumoto K., Nakamura T. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit. Rev. Oncol./Hemat. 2005, 53:35-69.
159. Joglar B., Rodriguez-Pallares J., Rodriguez-Perex A.I., Rey P., Guerra M.J., Labandeira-Garcia J.L. The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J. Neurochem. 2009, 109:656-669.
160. Johnson A.K., Epstein A.N. The cerebral ventricles as the avenue for the dipsogenic action of intracranial angiotensin. Brain Res. 1975, 86:399-418.
161. Johnston C.I. Biochemistry and pharmacology of the renin-angiotensin system. Drugs 1990, 39:21-31.
162. Kakar S.S., Sellers J.C., Devor D.C., Musgrove L.C., Neill J.D. Angiotensin II type-1 receptor subtype cDNAs: differential tissue expression and hormonal regulation. Biochem. Biophys. Res. Commun. 1992, 31:1090-1096.
163. Kambayashi Y., Bardhan S., Takahashi K., Tsuzuki S., Inui T., Hamakubo T., Inagami Y. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J. Biol. Chem. 1993, 268:24543-24546.
164. Kandror K.V., Yu L., Pilch P.F. The major protein of GLUT4-containing vesicles, gp160, has aminopeptidase activity. J. Biol. Chem. 1994, 269:30777-30780.
165. Karamyan V.T., Speth R.C. Enzymatic pathways of the brain renin-angiotensin system: unsolved problems and continuing challenges. Regul. Pept. 2007, 143:15-27.
166. Keller S.R., Scott H.M., Mastick C.C., Aebersold R., Lienhard G.E. Cloning and characterization of a novel insulin-regulated membrane aminopeptidase from Glut4 vesicles. J. Biol. Chem. 1995, 270:23612-23618.
167. Kerins D.M., Hao Q., Baughan D.E. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J. Clin. Invest. 1995, 96:2515-2520.
168. Khachaturian A.S., Zandi P.P., Lyketsos C.G., Hayden K.M., Skoog I., Norton M.C., Tschanz J.T., Mayer L.S., Welsh-Bohmer K.A., Breitner J.C. Antihypertensive medication use and incident Alzheimer disease: the Cache County study. Arch. Neurol. 2006, 63:686-692.
169. Konoshi H., Kuroda S., Inada Y., Fujisawa Y. Novel subtype of human angiotensin II type 1 receptor: cDNA cloning and expression. Biochem. Biophys. Res. Commun. 1994, 199:467-474.
170. Korhonen L., Sjoholm U., Takei N., Kern M.A., Schirmacher P., Castren E., Lindholm D. Expression of c-Met in developing rat hippocampus: evidence for HGF as a neurotrophic factor for calbindin D-expressing neurons. Eur. J. Neurosci. 2000, 12:3453-3461.
171. Kramár E.A., Armstrong D.L., Ikeda S., Wayner M.J., Harding J.W., Wright J.W. The effects of angiotensin IV analogs on long-term potentiation within the CA1 region of the hippocampus in vitro. Brain Res. 2001, 897:114-121.
172. Kramár E.A., Krishnan R., Harding J.W., Wright J.W. Role of nitric oxide in angiotensin IV-induced increases in cerebral blood flow. Regul. Pept. 1998, 74:185-192.
173. Kramár E.A., Harding J.W., Wright J.W. Angiotensin II- and IV-induced changes in cerebral blood flow. Roles of AT1, AT2, and AT4 receptor subtypes. Regul. Pept. 1997, 68:131-138.
174. Krause M.B., Pankow K., Becker M., Gembardt F., Alenina N., Walther T., Bader M., Siems W.E. Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J. 2005, 19:1474-1481.
175. Krebs L.T., Kramar E.A., Hanesworth J.M., Sardinia M.F., Ball A.E., Wright J.W., Harding J.W. Characterization of the binding properties and physiological action of divalinal-angiotensin IV, a putative AT4 receptor antagonist. Regul. Pept. 1996, 67:123-130.
176. Kril J.J., Halliday G.M., Svoboda M.D., Cartwright H. The cerebral cortex is damaged in chronic alcoholics. Neuroscience 1997, 79:983-998.
177. Krishnan R., Hanesworth J.M., Wright J.W., Harding J.W. Structure-binding studies of the adrenal AT4 receptor: analysis of position two- and three-modified angiotensin IV analogs. Peptides 1999, 20:915-920.
178. Kunz J., Krause D., Kremer M., Dermietzel R. The 140-kDa protein of blood-brain barrier-associated pericytes is identical to aminopeptidase N. J. Neurochem. 1994, 62:2375-2386.
179. Kurtz T.W., Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens. Res. 2009, 32:826-834.
180. Lanckmans K., Stragier B., Sarre S., Smoders I., Michotte Y. Nano-LC-MS/MS for the monitoring of angiotensin IV in rat brain microdialysates: limitations and possibilities. J. Sep. Sci. 2007, 30:2217-2224.
181. Lanckmans K., Sarre S., Smolders I., Michotte Y. Use of a structural analogue versus a stable isotope labeled internal standard for the quantification of angiotensin IV in rat brain dialysates using nano-liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2007, 21:1187-1195.
182. Lee J., Albiston A.L., Allen A.M., Mendelsohn F.A., Ping S.E., Barrett G.L., Murphy M., Morris M.J., McDowall S.G., Chai S.Y. Effect of ICV injection of AT4 receptor ligands, NLE1 angiotensin IV and LVV-hemorphin 7, on spatial learning in rats. Neuroscience 2004, 124:341-349.
183. Lee J., Chai S.Y., Mendelsohn F.A., Morris M.J., Allen A.M. Potentiation of cholinergic transmission in the rat hippocampus by angiotensin IV and LVV-hemorphin-7. Neuropharmacology 2001, 40:618-623.
184. Lee J., Mustafa T., McDowall S.G., Mendelsohn F.A., Brennan M., Lew R.A., Albiston A.L., Chai S.Y. Structure-activity study of LVV-hemorphin-7: angiotensin AT4 receptor ligand and inhibitor of insulin-regulated aminopeptidase. J. Pharmacol. Exp. Ther. 2003, 305:205-211.
185. Leong D.S., Terron J.A., Falcon-Neri A., Armando I., Ito T., Johren O., Tonelli L.H., Hoe K.L., Saavedra J.M. Restraint stress modulates brain, pituitary and adrenal expression of angiotensin II AT(1A), AT(1B) and AT(2) receptors. Neuroendocrinology 2002, 75:227-240.
186. Lew R.A., Mustafa T., Ye S., McDowall S.G., Chai S.Y., Albiston A.L. Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP). J. Neurochem. 2003, 86:344-350.
187. Li F., Shetty A.K., Sugahara K. Neuritogenic activity of chondroitin/dermatan sulfate hybrid chains of embryonic pig brain and their mimicry from shark liver. Involvement of the pleiotrophin and hepatocyte growth factor signaling pathways. J. Biol. Chem. 2007, 282:2956-2966.
188. Li W.A., Li W.P., Yao Y.Y., Zhang W., Yin Y.Y., Wu G.C., Gong H.L. Glucocorticoids increase impairments in learning and memory due to elevated amyloid precursor protein expression and neuronal apoptosis in 12-month old mice. Eur. J. Pharmacol. 2010, 628:108-115.
189. Li Y.D., Block E.R., Patel J.M. Activation of multiple signaling modules is critical in angiotensin IV-induced lung endothelial cell proliferation. Am. J. Physiol. Lung. Cell. Mol. Physiol. 2002, 283:L7707.
190. Lingham T., Perlanski E., Grupp L.A. Angiotensin converting enzyme inhibitors reduce alcohol consumption: some possible mechanisms and important conditions for its therapeutic use. Alcohol. Clin. Exp. Res. 1990, 14:92-99.
191. Linkola J., Fyhrquist F., Nieminen M.M., Weber T.H., Tontti K. Renin-aldosterone axis in ethanol intoxication and hangover. Eur. J. Clin. Invest. 1976, 31:191-194.
192. Linkola J., Fyhrquist F., Yikahri R. Renin, aldosterone and cortisol during ethanol intoxication and hangover. Acta Physiol. Scan. 1979, 106:75-82.
193. Linkola J., Tikkanen I., Fyhrquist F., Rusi M. Renin, water drinking, salt preference and blood pressure in alcohol preferring and alcohol avoiding rats. Pharmacol. Biochem. Behav. 1980, 12:293-296.
194. Lochard N., Thibault G., Silversides D.W., Touyz R.M., Reudelhuber T.L. Chronic production of angiotensin IV in the brain leads to hypertension that is reversible with an angiotensin II AT1 receptor antagonist. Cir. Res. 2004, 94:1451-1457.
195. Lopez-Real A., Rey P., Soto-Otero R., Mendez-Alvarez E., Labandeira-Garcia J.L. Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of parkinsonism. J. Neurosci. Res. 2005, 81:865-873.
196. Luetscher J.A., Kraemer F.B., Wilson D.M., Schwartz H.D., Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N. Engl. J. Med. 1985, 312:1412-1417.
197. Lukaszuk A., Demaegdt H., Feytens D., Vanderheyden P., Vauquelin G., Tourwe D. The replacement of His(4) in angiotensin IV by conformationally constrained residues provides highly potent and selective analogues. J. Med. Chem. 2009, 52:5612-5618.
198. Ma P.C., Maulik G., Christensen J., Salgia R. C-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003, 22:309-325.
199. Martin P., Massol J., Puech A.J. Captopril as an antidepressant? Effects on the learned helplessness paradigm in rats. Biol. Psychiatry 1990, 27:968-974.
200. Martins G.J., Plachez C., Powell E.M. Loss of embryonic MET signaling alters profiles of hippocampal interneurons. Dev. Neurosci. 2007, 29:143-158.
201. Matsoukas J.M., Goghari M.H., Scanlon M.N., Franklin K.J., Moore G.J. Synthesis and biological activities of analogues of angiotensins II and III containing O-methyltyrosine and D-tryptophan. J. Med. Chem. 1985, 28:780-783.
202. Matsumoto H., Nagasaka T., Hattori A., Rogi T., Tsuruoka N., Mizutani S., Tsujimoto M. Expression of placental leucine aminopeptidase/oxytocinase in neuronal cells and its action on neuronal peptides. Eur. J. Biochem. 2001, 268:3259-3266.
203. Matzke A., Sargsyan V., Holtmann B., Aramuni G., Asan E., Sendtner M., Pace G., Howells N., Zhang W., Ponta H., Orian-Rousseau V. Haplo insufficiency of c-Met in cd44-/- mice identifies a collaboration of CD44 and c-Met in vivo. Mol. Cell Biol. 2007, 27:8797-8806.
204. Mauer M., Zinman B., Gardiner R., Drummond K.N., Suissa S., Donnelly S.M., Strand T.D., Kramer M.S., Klein R., Sinaiko A.R. ACE-I and ARBs in early diabetic nephropathy. J. Renin Angiotensin Aldosterone Syst. 2002, 3:262-269.
205. McKinley M.J., Albiston A.L., Allen A.M., Mathai M.L., May C.N., McAllen R.M., Oldfield B.J., Mendelsohn F.A., Chai S.Y. The brain renin-angiotensin system: location and physiological roles. Int. J. Biochem. Cell Biol. 2003, 35:901-918.
206. Meighan P.C., Meighan S.E., Davis C.J., Wright J.W., Harding J.W. Effects of matrix metalloproteinase inhibition on short- and long-term plasticity of schaffer collateral/CA1 synapses. J. Neurochem. 2007, 102:2085-2096.
207. Meighan S.E., Meighan P.C., Choudhury P., Davis C.J., Olson M.L., Zornes P.A., Wright J.W., Harding J.W. Effects of extracellular matrix-degrading proteases matrixmetalloproteinases 3 and 9 on spatial learning and synaptic plasticity. J. Neurochem. 2006, 96:1227-1241.
208. Mentlein R., Roos T. Proteases involved in the metabolism of angiotensin II, bradykinin, calcitonin gene-related peptide (CGRP), and neuropeptide Y by vascular smooth muscle cells. Peptides 1996, 17:709-720.
209. Mertens B., Vanderheyden P., Michotte Y., Sarre S. The role of the central renin-angiotensin system in Parkinson's disease. J. Renin-Angiotensin-Aldosterone Syst. 2010, 11:49-56.
210. Mittrucker H.W., Steeg C., Malissen B., Fleischer B. The cytoplasmic tail of the T cell receptor zeta chain is required for signaling via CD26. Eur. J. Immunol. 1995, 25:295-297.
211. Miyazawa T., Matsumoto K., Ohmichi H., Katoh H., Yamashima T., Hakamura T. Protection of hippocampal neurons from ischemia-induced delayed neuronal death by hepatocyte growth factor: a novel neurotrophic factor. J. Cereb. Blood Flow Metab. 1998, 18:345-348.
212. Moeller I., Albiston A.L., Lew R.A., Mendelsohn F.A., Chai S.Y. A globin fragment, LVV-hemorphin-7, induces [3H]thymidine incorporation in a neuronal cell line via the AT4 receptor. J. Neurochem. 1999, 73:301-308.
213. Moeller I., Lew R.A., Mendelsohn F.A., Smith A.I., Brennan M.E., Tetaz T.J., Chai S.Y. The globin fragment LVV-hemorphin-7 is an endogenous ligand for the AT4 receptor in the brain. J. Neurochem. 1997, 68:2530-2537.
214. Moeller I., Small D.H., Reed G., Harding J.W., Mendelsohn F.A., Chai S.Y. Angiotensin IV inhibits neurite outgrowth in cultured embryonic chicken sympathetic neurons. Brain Res. 1996, 725:61-66.
215. Mogi M., Horiuchi M. Effects of angiotensin II receptor blockers on dementia. Hypertens. Res. 2009, 32:738-740.
216. Morishita R., Nakamura S., Hayashi S., Taniyama Y., Moriguchi A., Nagano T., Taiji M., Noguchi H., Takeshita S., Matsumoto K., Nakamura T., Higaki J., Ogihara T. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 1999, 33:1379-1384.
217. Mucke L. Neuroscience: Alzheimer's disease. Nature 2009, 461:895-897.
218. Mukoyama M., Kakajima M., Horiuchi M., Sasamura H., Pratt R.E., Dzau V.J. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven transmembrane receptors. J. Biol. Chem. 1993, 268:24539-24542.
219. Muller H., Kroger J., Johren O., Szymczak S., Bader M., Dominiak P., Raasch W. Stress sensitivity is increased in transgenic rats with low brain angiotensinogen. J. Endocrin. 2010, 204:85-92.
220. Munoz A., Rey P., Guerra M.J. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Neuropharmacology 2006, 51:112-120.
221. Murphy T.J., Alexander R.W., Griendling K.K., Runge M.S., Berstein K.E. Isolation of a cDNA encoding the vascular type-1 angiotensin receptor. Nature 1991, 351:233-236.
222. Mustafa T., Lee J.H., Chai S.Y., Albiston A.L., McDowall S.G., Mendelsohn F.A. Bioactive angiotensin peptides: focus on angiotensin IV. J. Renin Angiotensin Aldosterone Syst. 2001, 2:205-210.
223. Nakamura T., Muzuno S., Matsumoto K., Sawa Y., Matsuda H., Nakamura T. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J. Clin. Invest. 2000, 106:1511-1519.
224. Naveri L., Stromberg C., Saavedra J.M. Angiotensin IV reverses the acute cerebral blood flow reduction after experimental subarachnoid hemorrhage in the rat. J. Cereb. Blood Flow Metab. 1994, 14:1096-1099.
225. Nieminen M.M., Fyhrquist F., linkola J., Tikkanen I., Tontti K. Renin-aldosterone axis in ethanol intoxication. Pharmacol. Biochem. Behav. 1981, 15:879-882.
226. Nishimura Y., Ito T., Hoe K.L., Saavedra J.M. Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors. Brain Res. 2000, 871:29-38.
227. Obernier J.A., White A.M., Swartzwelder S., Crews F.T. Cognitive deficits and CNS damage after a 4-day binge ethanol exposure in rats. Pharmacol. Biochem. Behav. 2002, 72:521-532.
228. Ohno T., French L.C., Hirano S., Ossoff R.H., Rousseau B. Effect of hepatocyte growth factor on gene expression of extracellular matrix during wound healing of the injured rat vocal fold. Ann. Otol. Rhinol. Laryngol. 2008, 117:696-702.
229. Okamura A., Rakugi H., Ohishi M., Yanagitani Y., Takiuchi S., Moriguchi K., Fennessy P.A., Higaki J., Ogihara T. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J. Hypertens. 1999, 17:537-545.
230. Olson M.L., Olson E.A., Qualls J.H., Stratton J.J., harding J.W., Wright J.W. Norleucine1-angiotensin IV alleviates mecamylamine-induced spatial memory deficits. Peptides 2004, 25:233-241.
231. Onozato M.L., Tojo A., Goto A., Fujita T., Wilcox C.S. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int. 2002, 61:186-194.
232. Overmier J.B., Murison R. Anxiety and helplessness in the face of stress predisposes, precipitates, and sustains gastric ulceration. Brain Res. 2000, 110:161-174.
233. Pavel J., Benicky J., Murakami Y., Sanchez-Lemus E., Saavedra J.M. Peripherally administered angiotensin II AT1 receptor antagonists are anti-stress compounds in vivo. Ann. N. Y. Acad. Sci. 2008, 36:360-366.
234. 4 receptor subtype in overcoming scopolamine-induced spatial memory deficits. Regul. Pept. 2001, 102:147-156.
235. Pelegrini-Da-Silva A., Rosa E., Guethe L.J., Juliano M.A., Prado W.A., Martins A.R. Angiotensin III modulates the nociceptive control mediated by the periaquaductal gray matter. Neuroscience 2009, 164:1263-1273.
236. Peng J., Phillips M.I. Opposite regulation of brain angiotensin type 1 and type 2 receptors in cold-induced hypertension. Regul. Pept. 2001, 97:91-102.
237. Pfefferbaum A., Kim K.O., Zipursky R.B., Mathalon D.H., Lane B., Ha C.N., Sullivan E.V. Brain gray and white matter volume loss accelerates with aging in chronic alcoholics: a quantitative MRI study. Alcohol: Clin. Exp. Res. 1992, 16:1078-1089.
238. Phillips M.I. Functions of angiotensin in the central nervous system. Annu. Rev. Physiol. 1987, 49:413-435.
239. Phillips M.I., Felix D. Specific angiotensin II receptive neurons in the cat subfornical organ. Brain Res. 1976, 109:531-540.
240. Phillips M.I., Menezes de Oliveira E. Brain renin angiotensin in disease. J. Mol. Med. 2008, 86:715-722.
241. Phillips M.I., Mann J.F., Haebara H., Hoffman W.E., Dietz R., Schelling P., Ganten D. Lowering of hypertension by central saralasin in the absence of plasma renin. Nature 1977, 270:445-447.
242. Powell E.M., Muhlfriedel S., Bolz J., Levitt P. Differential regulation of thalamic and cortical axonal growth by hepatocyte growth factor/scatter factor. Dev. Neurosci. 2003, 25:197-206.
243. Price D.A., Porter L.E., Gordon M., Fisher N.D., De'Oliveira J.M., Laffel L.M., Passan D.R., Williams G.H., Hollenberg N.K. The paradox of the low-renin state in diabetic nephropathy. J. Am. Soc. Nephrol. 1999, 10:2382-2391.
244. Prozherina Y.A. Involvement of angiotensin II and angiotensin IV in producing the individual characteristics of defensive and feeding behavior in rats. Neurosci. Behav. Physiol. 2008, 38:563-572.
245. Przegalinski E., Siwanowicz J., Baran L. Effect of repeated administration of antidepressant drugs on the isoprenaline-induced drinking in rats. Pol. J. Pharmacol. 1988, 40:251-258.
246. Ramírez M., Arechage G., García S., Sanchez B., De Gandarias J.M. Mn2(+)-activated aspartate aminopeptidase activity, subcellular localization in young and adult rat brain. Brain Res. 1990, 522:165-167.
247. Reardon K.A., Mendelsohn F.A., Chai S.Y., Horne M.K. The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease. Aust. N. Z. J. Med. 2000, 30:48-53.
248. Reudelhuber T.L. The renin-angiotensin system: peptides and enzymes beyond angiotensin II. Curr. Opin. Nephrol. Hypertens. 2005, 14:155-159.
249. Rey P., Lopez-Real A., Sanchez-Iglesias S., Munoz A., Soto-Otero R., Labandeira-Garcia J.L. Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons. Neurobiol. Aging 2007, 28:555-567.
250. Ribeiro-Oliveira A., Nogueira A.I., Pereira R.M., Roas W.W., Santos R.A., e Silva A.C. The renin-angiotensin system and diabetes: an update. Vasc. Health Risk Manag. 2008, 4:787-803.
251. Rich D.H., Moon B.J., Harbeson S. Inhibition of aminopeptidases by amastatin and bestatin derivatives, effect of inhibitor structure on slow-binding processes. J. Med. Chem. 1984, 27:417-422.
252. 3-angiotensin(1-7) accelerate healing in dermal models. J. Peptide Res. 2006, 66(Suppl. 1):41-47.
253. Rodriguez-Pallares J., Rey P., Parga J.A., Munoz A., Guerra M.J., Labandeira-Garcia J.L. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol. Dis. 2008, 31:58-73.
254. Rogi T., Tsujimoto M., Nakazato H., Mizutani S., Tomoda Y. Human placental leucine aminopeptidase/oxytocinase. A new member of type II membrane-spanning zinc metallopeptidase family. J. Biol. Chem. 1996, 271:56-61.
255. 2 receptor in inflammation. Drug News Perspect. 2010, 23:104-111.
256. Ross S.A., Scott H.M., Morris N.J., Leung W.Y., Mao F., Lienhard G.E., Keller S.R. Characterization of the insulin-regulated membrane aminopeptidase in 3T3-L1 adipocytes. J. Biol. Chem. 1996, 271:3328-3332.
257. Rothman S.M., Mattson M.P. Adverse stress, hippocampal networks, and Alzheimer's disease. Neuromol. Med. 2010, 12:56-70.
258. Saab Y.B., Gard P.R., Yeoman M.S., Mfarrej B., El-Moalem H., Ingram M.J. Renin-angiotensin-system gene polymorphisms and depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1113-1118.
259. Saavedra J.M. Brain and pituitary angiotensin. Endocr. Rev. 1992, 13:329-380.
260. Saavedra J.M. Emerging features of brain angiotensin receptors. Regul. Pept. 1999, 85:31-45.
261. Saavedra J.M., Benicky J. Brain and peripheral angiotensin II play a major role in stress. Stress 2007, 10:185-193.
262. Sadamura H., Hein L., Krieger J.E., Pratt R.E., Kobilka B.K., Dzau V.J. Cloning, characterization, and expression of two angiotensin receptor (AT-1) isoforms from the mouse genome. Biochem. Biophys. Res. Commun. 1992, 185:253-259.
263. Sandberg K., Ji H., Catt K.J. Regulation of angiotensin II receptors in rat brain during dietary sodium changes. Hypertension 1994, 23. I-137-I-141.
264. Santos A.N., Langner J., Herrmann M., Riemann D. Aminopeptidase N/CD13 is directly linked to signal transduction pathways in monocytes. Cell Immunol. 2000, 201:22-32.
265. Sardinia M.F., Hanesworth J.M., Krebs L.T., Harding J.W. AT4 receptor binding characteristics: D-amino acid- and glycine-substituted peptides. Peptides 1993, 14:949-954.
266. Sardinia M.F., Hanesworth J.M., Krishnan F., Harding J.W. AT4 receptor structure-binding relationship: N-terminal-modified angiotensin IV analogues. Peptides 1994, 15:1399-1406.
267. Sasaki K., Yamano Y., Bardhan S., Iwai N., Murray J.J., Hasegawa M., Matsuda Y., Inagami T. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature (Lond.) 1991, 351:230-233.
268. Savaskan E., Hock C., Olivieri G., Bruttel S., Rosenberg C., Huylette C., Muller-Spahn F. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol. Aging 2001, 22:541-546.
269. Sayeski P.P., Ali M.S., Semeniuk D.J., Doan T.N., Bernstein K.E. Angiotensin II signal transduction pathways. Regul. Pept. 1998, 78:19-29.
270. Schefe J.H., Menk M., Reinemund J., Effertz K., Hobbs R.M., Pandolfi P.P., Ruiz P., Unger T., Funke-Kaiser H. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ. Res. 2006, 99:1355-1366.
271. Schmitz Y., Luccarelli J., Kim M., Wang M., Sulzer D. Glutamate controls growth rate and branching of dopaminergic axons. J. Neurosci. 2009, 29:11973-11981.
272. Shah k., Qureshi S.U., Johnson M., Parikh N., Schulz P.E., Kunik M.E. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am. J. Geriatr. Pharmacother. 2009, 7:250-261.
273. Shang J., Deguchi K., Ohta Y., Liu N., Zhang X., Tian F., Yamashita T., Ikeda Y., Matsuura T., Funakoshi H., Nakamura T., Abe K. Strong neurogenesis, angiogenesis, synaptogenesis, and antifibrosis of hepatocyte growth factor in rats brain after transient middle cerebral artery occlusion. J. Neurosci. 2011, 89:86-95.
274. Sharma S.K. Hepatocyte growth factor in synaptic plasticity and Alzheimer's disease. Sci. World J. 2010, 10:457-461.
275. Shimamura M., Sato N., Waguri S., Uchiyama Y., Hayashi T., Iida H., Nakamura T., Ogihara T., Kaneda Y., Morishita R. Gene transfer of hepatocyte growth factor gene improves learning and memory in the chronic stage of cerebral infarction. Hypertension 2006, 47:742-751.
276. Siragy H.M. Comparing angiotensin II receptor blockers on benefits beyond blood pressure. Adv. Ther. 2010, 27:257-284.
277. Sjolie A.K., Klein R., Porta M., Orchard T., Fuller J., Parving H.H., Biolous R., Chaturvedi N. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomized placebo-controlled trial. Lancet 2008, 372:1385-1393.
278. Sommer W.H., Saavedra J.M. Targeting brain angiotensin and corticotrophin-releasing hormone systems interaction for the treatment of mood and alcohol use disorders. J. Mol. Med. 2008, 86:723-728.
279. Speth R.C., Brown T.E., Barnes R.D., Wright J.W. Brain angiotensinergic activity: the state of our current knowledge. Proc. West. Pharmacol. Soc. 2003, 46:11-15.
280. Speth R.C., Karamyan V.T. The significance of brain aminopeptidases in the regulation of the actions of angiotensin peptides in the brain. Heart Fail. Rev. 2008, 13:299-309.
281. Speth R.C., Thompson S.M., Johns S.J. Angiotensin II receptors: structural and functional considerations. Current Concepts: Tissue Renin Angiotensin Systems as Local Regulators in Reproductive and Endocrine Organs 1995, 169-192. Plenum Press, New York. A.K. Mukhopadhyay, M.K. Raizada (Eds.).
282. Spinosa G., Perlanski E., Leenen F.H., Stewart R.B., Grupp L.A. Angiotensin converting enzyme inhibitors: animal experiments suggest a new pharmacological treatment for alcohol abuse in humans. Alcohol Clin. Exp. Res. 1988, 12:65-70.
283. Steckelings U.M., Rompe F., Kaschina E., Unger T. The evolving story of the RAAS in hypertension, diabetes and CV disease-moving from macrovascular to microvascular targets. Fundam. Clin. Pharmacol. 2009, 23:693-703.
284. Steckelings U.M., Unger T. The renin-angiotensin-aldosterone system. Manual of Hypertension of the European Society of Hypertension 2008, vol. 14:110-116. Informa Healthcare, London, UK.
285. Stragier B., Clinckers R., Meurs A., De Bundel D., Sarre S., Ebinger G., Michotte Y., Smolders I. Involvement of the somatostatin-2 receptor in the anti-convulsant effect of angiotensin IV against pilocarpine-induced limbic seizures in rats. J. Neurochem. 2006, 98:1100-1113.
286. Stragier B., De Bundel D., Sarre S., Smolders I., Vauguelin G., Dupont A., Michotte Y., Vanderheyden P. Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review. Heart Fail. Rev. 2008, 13:321-337.
287. Stragier B., Sarre S., Vanderheyden P., Vauquelin G., Fournie-Zaluski M.C., Ebinger G., Michotte Y. Metabolism of angiotensin II is required for its in vivo effect on dopamine release in the striatum of the rat. J. Neurochem. 2004, 90:1251-1257.
288. Strittmatter S.M., Thiele E.A., Kapiloff M.S., Snyder S.H. A rat brain isozyme of angiotensin-converting enzyme. Unique specificity for amidated peptide substrates. J. Biol. Chem. 1985, 260:9825-9832.
289. Stubley-Weatherly L., Harding J.W., Wright J.W. Effects of discrete kainic acid-induced hippocampal lesions on spatial and contextual learning and memory in rats. Brain Res. 1996, 716:29-38.
290. Sullivan E.V., Marsh L., Mathalon D.H., Lim K.O., Pfefferbaum A. Anterior hippocampal volume deficits in nonamnesic, aging chronic alcoholics. Alcohol: Clin. Exp. Res. 1995, 19:110-122.
291. Swanson G.N., Hanesworth J.M., Sardinia M.F., Coleman J.K., Wright J.W., Hall K.L., Miller-Wing A.V., Stobb J.W., Cook V.I., Harding E.C., Harding J.W. Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regul. Pept. 1992, 40:409-419.
292. Tada R., Zhan H., Tanaka Y., Hongo K., Matsumoto K., Nakamura T. Intraventricular administration of hepatocyte growth factor treats mouse communicating hydrocephalus induced by transforming growth factor beta1. Neurobiol. Dis. 2006, 21:576-585.
293. Takeda S., Sato N., Takeuchi D., Kurinami H., Shinohara M., Niisato K., Kano M., Ogihara T., Rakugi H., Morishita R. Angiotensin receptor blocker prevented β-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 2009, 54:1345-1352.
294. Takeo S., Takagi N., Takagi K. Ischemic brain injury and hepatocyte growth factor. Yakugaku Zasshi 2007, 127:1813-1823.
295. Takeuchi D., Sato N., Shimamura M., Kurinami H., Takeda S., Shinohara M., Suzuki S., Kojima M., Ogihara T., Morishita R. Alleviation of Abeta-induced cognitive impairment by ultrasound-mediated gene transfer of HGF in a mouse model. Gene Ther. 2008, 15:561-571.
296. Tchekalarova J.D., Georgiev V.P. Adenosine-angiotensin II interactions in pentylenetetrazol seizure threshold in mice. J. Physiol. (Paris) 1999, 93:191-197.
297. Tchekalarova J.D., Georgiev V.P. Angiotensin peptides modulatory system: how is it implicated in the control of seizure susceptibility?. Life Sci. 2005, 76:955-970.
298. Tchekalarova J.D., Georgiev V.P. Ang II and Ang III modulate PTZ seizure threshold in non-stressed and stressed mice: possible involvement of noradrenergic mechanism. Neuropeptides 2006, 40:339-348.
299. 1 receptors. Brain Res. Bull. 2001, 56:87-91.
300. Tchekalarova J.D., Pehlivanova D., Kambourova T., Matsoukas J., Georgiev V. The effects of sarmesin, an angiotensin II analogue on seizure susceptibility, nociception and memory retention. Regul. Pept. 2003, 111:191-197.
301. Thathiah A., De Strooper B. G protein-coupled receptors, cholinergic dysfunction, and Abeta toxicity in Alzheimer's disease. Sci. Signal 2009, 2:re8.
302. Thewke E.P., Seeds N.W. The expression of mRNAs for hepatocyte growth factor/scatter factor, its receptor c-met, and one of its activators tissue-type plasminogen activator show a systematic relationship in the developing and adult cerebral cortex and hippocampus. Brain Res. 1999, 821:356-367.
303. Thomas W.G., Mendelsohn F.A.O. Molecules in focus: angiotensin receptors: form and function and distribution. Int. J. Biochem. Cell Biol. 2003, 35:774-779.
304. Tota S., Kamat P.K., Awasthi H., Singh N., Raghubir R., Nath C., Hanif K. Candesartan improves memory decline in mice: involvement of AT1 receptors in memory deficit induced by intracerebral streptozoticin. Behav. Brain Res. 2009, 199:235-240.
305. Tsuboi Y., Kakimoto K., Nakajima M., Akatsu H., Yamamoto T., Ogawa K., Ohnishi T., Daikuhara Y., Yamada T. Increased hepatocyte growth factor level in cerebrospinal fluid in Alzheimer's disease. Acta Neurol. Scand. 2003, 107:81-86.
306. Tsukuda K., Mogi M., Iwanami J., Min L.J., Sakata A., Jing F., Iwai M., Horiuchi M. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. Hypertension 2009, 54:782-787.
307. Tsuzuki N., Miyazawa T., Matsumoto K., Hakamura T., Shima K. Hepatocyte growth factor reduces the infarct volume after transient focal cerebral ischemia in rats. Neurol. Res. 2001, 23:417-424.
308. Tuncel N., Erkasap N., Sahinturk V., Ak D.D., Tuncel M. The protective effect of vasoactive intestinal peptide (VIP) on stress-induced gastric ulceration in rats. Ann. N.Y. Acad. Sci. 1998, 865:309-322.
309. Tyndall S.J., Patel S.J., Walikonis R.S. Hepatocyte growth factor-induced enhancement of dendritic branching is blocked by inhibitors of N-methyl-D-aspartate receptors and calcium/calmodulin-dependent kinases. J. Neurosci. Res. 2007, 85:2343-2351.
310. Tyndall S.J., Walikonis R.S. The receptor tyrosine kinase Met and its ligand hepatocyte growth factor are clustered at excitatory synapses and can enhance clustering of synaptic proteins. Cell Cycle 2006, 5:1560-1568.
311. Tyndall S.J., Walikonis R.S. Signaling by hepatocyte growth factor in neurons is induced by pharmacological stimulation of synaptic activity. Synapse 2007, 61:199-204.
312. Unger T. The role of the renin-angiotensin-aldosterone system in heart failure. J. Renin Angiotensin Aldosterone Syst. 2004, 5:S7-S10.
313. Unger T., Badoer E., Ganten D., Lang R.E., Rettig R. Brain angiotensin: pathways and pharmacology. Circulation 1988, 77:140-154.
314. Van Belle E., Witzenbichler B., Chen D., Silver M., Chang L., Schwall R., Isner J.M. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 1998, 97:381-390.
315. Vanderheyden P.M. From angiotensin IV binding site to AT4 receptor. Mol. Cell Endocrinol. 2009, 302:159-166.
316. Vaughan D.E. Angiotensin and vascular fibrinolytic balance. Am. J. Hypertens. 2002, 15(1 Pt2). pp. 3S-8S.
317. Vauquelin G., Michotte Y., Smolders I., Sarre S., Ebinger G., Dupont A., Vanderheyden P. Cellular targets for angiotensin II fragments: pharmacological and molecular evidence. J. Renin-Angiotensin-Aldosterone Syst. 2002, 3:195-204.
318. von Bohlen und Halbach, O., 2003. Angiotensin IV in the central nervous system. Cell Tissue Res. 311, 1-9.
319. von Bohlen und Halbach, O., Albrecht, D., 1998. Opposite effects of angiotensin II and IV in the lateral nucleus of the amygdala. Brain Res. Bull. 47, 311-315.
320. von Bohlen und Halbach, O., Albrecht, D., 2006. The CNS renin-angiotensin system. Cell Tissue Res. 326, 599-616.
321. Wallis M.G., Lankford M.F., Keller S.R. Vasopressin is a physiological substrate for the insulin-regulated aminopeptidase IRAP. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E1092-E1102.
322. Wang J., Ho L., Chen L., Zhoa Z., Zhao W., Qian X., Humala N., Seror I., Bartholomew S., Rosendorff C., Pasinetti G.M. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J. Clin. Invest. 2007, 117:3393-3402.
323. Washida K., Ihara M., Nishio K., Fujita Y., Maki lT., Yamada M., Takahashi J., Wu X., Kihara T., Ito H., Tomimoto H., Takahashi R. Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-gamma activation in mice with chronic cerebral hypoperfusion. Stroke 2010, 41:1798-1806.
324. Wayner M.J., Armstrong D.L., Phelix C.F., Wright J.W., Harding J.W. Angiotensin IV enhances LTP in rat dentate gyrus in vivo. Peptides 2001, 22:1403-1414.
325. Weisinger R.S., Blair-West J.R., Burns P., Denton D.A. Intracerebroventricular infusion of angiotensin II increase water and ethanol intake in rats. Am. J. Physiol. 1999, 277:R162-R172.
326. Wilk S., Healy D.P. Glutamyl aminopeptidase (aminopeptidase A), the BP-1/6C3 antigen. Adv. Neuroimmunol. 1993, 3:195-207.
327. Woo K.T., Wong K.S., Chan C.M. Clinical trials of the past decade in the management of chronic kidney disease. Rev. Recent Clin. Trials 2009, 4:159-162.
328. Wright J.W., Harding J.W. Regulatory role of brain angiotensins in the control of physiological and behavioral responses. Brain Res. Rev. 1992, 17:227-262.
329. Wright J.W., Harding J.W. Important roles for angiotensin III and IV in the brain renin-angiotensin system. Brain Res. Rev. 1997, 25:96-124.
330. Wright J.W., Harding J.W. The brain angiotensin system and extracellular matrix molecules in neural plasticity, learning, and memory. Prog. Neurobiol. 2004, 72:263-293.
331. 4 receptor system as a new target for the treatment of Alzheimer's disease. Drug Dev. Res. 2009, 70:472-480.
332. Wright J.W., Harding J.W. The brain RAS and Alzheimer's disease. Exp. Neurol. 2010, 223:326-333.
333. Wright J.W., Bechtholt A.J., Chambers S.L., Harding J.W. Angiotensin III and IV activation of the brain AT1 receptor subtype in cardiovascular function. Peptides 1996, 17:1365-1371.
334. Wright J.W., Clemens J.A., Panetta J.A., Smalstig E.B., Weatherly L.A., Kramár E.A., Pederson E.S., Mungall B.H., Harding J.W. Effects of LY231617 and angiotensin IV on ischemia-induced deficits in circular water maze and passive avoidance performance in rats. Brain Res. 1996, 717:1-11.
335. Wright J.W., Kramár E.A., Meighan S.E., Harding J.W. Extracellular matrix molecules, long-term potentiation, memory consolidation and the brain angiotensin system. Peptides 2002, 23:221-246.
336. Wright J.W., Kramár E.A., Myers E.d., Davis C.J., Harding J.W. Ethanol-induced suppression of LTP can be attenuated with an angiotensin IV analog. Regul. Pept. 2003, 113:49-56.
337. Wright J.W., Krebs L.T., Stobb J.W., Harding J.W. The angiotensin IV system: functional implications. Front. Neuroendocrinol. 1995, 16:23-52.
338. Wright J.W., Miller-Wing A.V., Shaffer M.J., Higginson C., Wright D.E., Hanesworth J.M., Harding J.W. Angiotensin II(3-8) (ANG IV) hippocampal binding: potential role in the facilitation of memory. Brain Res. Bull. 1993, 32:497-502.
339. Wright J.W., Morseth S.L., Abhold R.H., Harding J.W. Elevations in plasma angiotensin II with prolonged ethanol treatment in rats. Pharmcol. Biochem. Behav. 1986, 24:813-818.
340. 4 receptor subtype system to spatial learning. J. Neurosci. 1999, 19:3952-3961.
341. Wright J.W., Yamamoto B.J., Harding J.W. Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets. Prog. Neurobiol. 2008, 84:157-181.
342. Xu K.P., Yu F.S. Cross talk between c-Met and epidermal growth factor receptor during retinal pigment epithelial wound healing. Invest. Ophthalmol. Vis. Sci. 2007, 48:2242-2248.
343. Yamagishi S., Amano S., Inagaki Y., Okamoto T., Inoue H., Takeuchi M., Choei H., Sasaki N., Kikuchi S. Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation. Drugs Exp. Clin. Res. 2003, 29:75-80.
344. 2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor. J. Pharmacol. Exp. Ther. 2010, 333:161-173.
345. Yang R., Smolders I., De Bundel D., Fouyn R., Halberg M., Demaegdt H., Vanderheyden P., Dupont A.G. Brain and peripheral angiotensin II type 1 receptors mediate renal vasoconstrictor and blood pressure responses to angiotensin IV in the rat. J. Hypertens. 2008, 26:998-1007.
346. Yang R., Walther T., Gembardt F., Smolders I., Vanderheyden P., Albiston A.L., Chai S.Y., Dupont A.G. Renal vasoconstrictor and pressor responses to angiotensin IV in mice are AT1a-receptor mediated. J. Hypertens. 2010, 28:487-494.
347. Zhao W., Wang J., Ho L., Ono K., Teplow D.B., Paninetti G.M. Identification of antihypertensive drugs which inhibit amyloid-β protein oligomerization. J. Alzheimers Dis. 2009, 16:49-57.
348. Zou J.Y., Martinez D.B., Neafsey E.J., Collins M.A. Binge ethanol-induced brain damage in rats: effects of inhibitors of nitric oxide synthase. Alcohol: Clin. Exp. Res. 1996, 20:1406-1411.
349. Zubenko G.S., Nixon R.A. Mood elevating effect of captopril in depressed patients. Am. J. Psychiatry 1984, 141:110-111.